vs
吉利德科学（GILD）与嘉信理财（SCHW）财务数据对比。点击上方公司名可切换其他公司
吉利德科学的季度营收约是嘉信理财的1.3倍（$7.9B vs $6.3B），嘉信理财净利率更高（38.8% vs 27.5%，领先11.3%），嘉信理财同比增速更快（18.9% vs 4.7%），吉利德科学自由现金流更多（$3.1B vs $-921.0M），过去两年嘉信理财的营收复合增速更高（15.6% vs 8.9%）
吉利德科学是总部位于美国加利福尼亚州福斯特城的生物制药企业，专注于研发抗病毒药物，覆盖艾滋病、乙型肝炎、丙型肝炎、流感、新冠等治疗领域，核心产品包括来迪派韦索磷布韦、索磷布韦等，现为纳斯达克100指数及标普100指数成分股。
嘉信理财是美国领先的金融服务企业，面向个人投资者、独立财务顾问及企业客户，提供零售与机构经纪、财富管理、银行服务、退休规划、投资咨询等解决方案，主打低成本高可及性的金融产品与数字化理财工具。
GILD vs SCHW — 直观对比
营收规模更大
GILD
是对方的1.3倍
$6.3B
营收增速更快
SCHW
高出14.2%
4.7%
净利率更高
SCHW
高出11.3%
27.5%
自由现金流更多
GILD
多$4.0B
$-921.0M
两年增速更快
SCHW
近两年复合增速
8.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $7.9B | $6.3B |
| 净利润 | $2.2B | $2.5B |
| 毛利率 | 79.5% | — |
| 营业利润率 | 25.0% | 50.2% |
| 净利率 | 27.5% | 38.8% |
| 营收同比 | 4.7% | 18.9% |
| 净利润同比 | 22.4% | 33.6% |
| 每股收益（稀释后） | $1.75 | $1.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GILDSCHW
| Q4 25 | $7.9B | $6.3B | ||
| Q3 25 | $7.8B | $6.1B | ||
| Q2 25 | $7.1B | $5.9B | ||
| Q1 25 | $6.7B | $5.6B | ||
| Q4 24 | $7.6B | $5.3B | ||
| Q3 24 | $7.5B | $4.8B | ||
| Q2 24 | $7.0B | $4.7B | ||
| Q1 24 | $6.7B | $4.7B |
净利润GILDSCHW
| Q4 25 | $2.2B | $2.5B | ||
| Q3 25 | $3.1B | $2.4B | ||
| Q2 25 | $2.0B | $2.1B | ||
| Q1 25 | $1.3B | $1.9B | ||
| Q4 24 | $1.8B | $1.8B | ||
| Q3 24 | $1.3B | $1.4B | ||
| Q2 24 | $1.6B | $1.3B | ||
| Q1 24 | $-4.2B | $1.4B |
毛利率GILDSCHW
| Q4 25 | 79.5% | — | ||
| Q3 25 | 79.8% | — | ||
| Q2 25 | 78.8% | — | ||
| Q1 25 | 76.9% | — | ||
| Q4 24 | 79.1% | — | ||
| Q3 24 | 79.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.8% | — |
营业利润率GILDSCHW
| Q4 25 | 25.0% | 50.2% | ||
| Q3 25 | 42.8% | 49.2% | ||
| Q2 25 | 34.9% | 47.9% | ||
| Q1 25 | 33.6% | 43.8% | ||
| Q4 24 | 32.4% | 43.3% | ||
| Q3 24 | 11.8% | 38.0% | ||
| Q2 24 | 38.0% | 37.2% | ||
| Q1 24 | -64.6% | 37.9% |
净利率GILDSCHW
| Q4 25 | 27.5% | 38.8% | ||
| Q3 25 | 39.3% | 38.4% | ||
| Q2 25 | 27.7% | 36.3% | ||
| Q1 25 | 19.7% | 34.1% | ||
| Q4 24 | 23.6% | 34.5% | ||
| Q3 24 | 16.6% | 29.0% | ||
| Q2 24 | 23.2% | 28.4% | ||
| Q1 24 | -62.4% | 28.7% |
每股收益（稀释后）GILDSCHW
| Q4 25 | $1.75 | $1.32 | ||
| Q3 25 | $2.43 | $1.26 | ||
| Q2 25 | $1.56 | $1.08 | ||
| Q1 25 | $1.04 | $0.99 | ||
| Q4 24 | $1.43 | $0.94 | ||
| Q3 24 | $1.00 | $0.71 | ||
| Q2 24 | $1.29 | $0.66 | ||
| Q1 24 | $-3.34 | $0.68 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $68.0M | $46.0B |
| 总债务越低越好 | $24.9B | $22.2B |
| 股东权益账面价值 | $22.7B | $49.4B |
| 总资产 | $59.0B | $491.0B |
| 负债/权益比越低杠杆越低 | 1.10× | 0.45× |
8季度趋势，按日历期对齐
现金及短期投资GILDSCHW
| Q4 25 | $68.0M | $46.0B | ||
| Q3 25 | $19.0M | $30.6B | ||
| Q2 25 | $69.0M | $32.2B | ||
| Q1 25 | — | $35.0B | ||
| Q4 24 | — | $42.1B | ||
| Q3 24 | — | $34.9B | ||
| Q2 24 | — | $25.4B | ||
| Q1 24 | — | $31.8B |
总债务GILDSCHW
| Q4 25 | $24.9B | $22.2B | ||
| Q3 25 | $24.9B | $20.2B | ||
| Q2 25 | $24.9B | $20.2B | ||
| Q1 25 | $25.0B | $21.5B | ||
| Q4 24 | $26.7B | $22.4B | ||
| Q3 24 | $23.2B | $22.4B | ||
| Q2 24 | $23.3B | $22.4B | ||
| Q1 24 | $25.2B | $22.9B |
股东权益GILDSCHW
| Q4 25 | $22.7B | $49.4B | ||
| Q3 25 | $21.5B | $49.4B | ||
| Q2 25 | $19.7B | $49.5B | ||
| Q1 25 | $19.2B | $49.5B | ||
| Q4 24 | $19.3B | $48.4B | ||
| Q3 24 | $18.5B | $47.2B | ||
| Q2 24 | $18.3B | $44.0B | ||
| Q1 24 | $17.5B | $42.4B |
总资产GILDSCHW
| Q4 25 | $59.0B | $491.0B | ||
| Q3 25 | $58.5B | $465.3B | ||
| Q2 25 | $55.7B | $458.9B | ||
| Q1 25 | $56.4B | $462.9B | ||
| Q4 24 | $59.0B | $479.8B | ||
| Q3 24 | $54.5B | $466.1B | ||
| Q2 24 | $53.6B | $449.7B | ||
| Q1 24 | $56.3B | $468.8B |
负债/权益比GILDSCHW
| Q4 25 | 1.10× | 0.45× | ||
| Q3 25 | 1.16× | 0.41× | ||
| Q2 25 | 1.27× | 0.41× | ||
| Q1 25 | 1.30× | 0.43× | ||
| Q4 24 | 1.38× | 0.46× | ||
| Q3 24 | 1.26× | 0.48× | ||
| Q2 24 | 1.28× | 0.51× | ||
| Q1 24 | 1.44× | 0.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $-763.0M |
| 自由现金流经营现金流 - 资本支出 | $3.1B | $-921.0M |
| 自由现金流率自由现金流/营收 | 39.4% | -14.5% |
| 资本支出强度资本支出/营收 | 2.6% | 2.5% |
| 现金转化率经营现金流/净利润 | 1.52× | -0.31× |
| 过去12个月自由现金流最近4个季度 | $9.5B | $8.8B |
8季度趋势，按日历期对齐
经营现金流GILDSCHW
| Q4 25 | $3.3B | $-763.0M | ||
| Q3 25 | $4.1B | $538.0M | ||
| Q2 25 | $827.0M | $3.2B | ||
| Q1 25 | $1.8B | $6.4B | ||
| Q4 24 | $3.0B | $-10.8B | ||
| Q3 24 | $4.3B | $19.1B | ||
| Q2 24 | $1.3B | $-4.3B | ||
| Q1 24 | $2.2B | $-1.3B |
自由现金流GILDSCHW
| Q4 25 | $3.1B | $-921.0M | ||
| Q3 25 | $4.0B | $393.0M | ||
| Q2 25 | $720.0M | $3.0B | ||
| Q1 25 | $1.7B | $6.2B | ||
| Q4 24 | $2.8B | $-11.1B | ||
| Q3 24 | $4.2B | $19.0B | ||
| Q2 24 | $1.2B | $-4.3B | ||
| Q1 24 | $2.1B | $-1.5B |
自由现金流率GILDSCHW
| Q4 25 | 39.4% | -14.5% | ||
| Q3 25 | 51.0% | 6.4% | ||
| Q2 25 | 10.2% | 52.1% | ||
| Q1 25 | 24.8% | 111.5% | ||
| Q4 24 | 37.4% | -207.9% | ||
| Q3 24 | 55.2% | 391.4% | ||
| Q2 24 | 17.2% | -92.6% | ||
| Q1 24 | 31.6% | -31.6% |
资本支出强度GILDSCHW
| Q4 25 | 2.6% | 2.5% | ||
| Q3 25 | 1.9% | 2.4% | ||
| Q2 25 | 1.5% | 2.2% | ||
| Q1 25 | 1.6% | 2.1% | ||
| Q4 24 | 1.9% | 4.8% | ||
| Q3 24 | 1.9% | 2.6% | ||
| Q2 24 | 1.9% | 1.9% | ||
| Q1 24 | 1.6% | 3.1% |
现金转化率GILDSCHW
| Q4 25 | 1.52× | -0.31× | ||
| Q3 25 | 1.35× | 0.23× | ||
| Q2 25 | 0.42× | 1.49× | ||
| Q1 25 | 1.34× | 3.33× | ||
| Q4 24 | 1.67× | -5.88× | ||
| Q3 24 | 3.44× | 13.56× | ||
| Q2 24 | 0.82× | -3.19× | ||
| Q1 24 | — | -0.99× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
SCHW
| Investor Services | $5.0B | 79% |
| Order Flow Revenue | $531.0M | 8% |
| Commissions | $482.0M | 8% |
| Other | $127.0M | 2% |
| Financial Service Other | $100.0M | 2% |
| Principal Transactions | $53.0M | 1% |
